The goal of treatment in AML is to reduce the blasts in the bone marrow to below 5% and return the blood cell counts to normal levels. This is considered a complete remission, or CR. A hematopoietic stem cell transplantation (HSCT), or bone marrow transplant, is generally recognized as the only curative treatment option. Typically, patients who are able to achieve a reduction in bone marrow blasts below 5% are more suitable candidates for an HSCT and have an improved projected outcome following an HSCT
As you may know Cabozantinib inhibits FLT3
NCT01961765---Under the radar and currently enrolling patients. This trial may sneak up and show some interesting data.
Here is a brief on Quizartinib FLT3 inhibitor
Quizartinib Phase 2 Clinical Trial
A Phase 2 clinical trial of quizartinib in relapsed/refractory AML patients was initiated in November 2009 and completed enrollment in November 2011. Data from our single-arm, 333 patient clinical trial was reported at the American Society of Hematology meeting in December 2012. In the trial, quizartinib demonstrated the ability to significantly reduce the number of blasts in the bone marrow of a substantial number of patients.
Our Phase 2 clinical trial demonstrated the following three key clinical outcomes:
1.Quizartinib, as a monotherapy, demonstrated approximately a 50% CRc response rate in relapsed/refractory FLT3-ITD positive patients;
2.A substantial number of patients treated with quizartinib were bridged to a potentially curative hematopoietic stem cell transplantation, or an HSCT (commonly referred to as a bone marrow transplant); and
3.Overall survival in FLT3-ITD positive patients treated with quizartinib compared favorably to historical survival data reported for both FLT3-ITD positive and negative AML patients.
In addition, nearly one of every five patients treated with quizartinib (irrespective of FLT3-ITD status) remained alive for more than 12 months and such patients are referred to as long term survivors.